Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group
50
Zitationen
17
Autoren
2024
Jahr
Abstract
Brain tumor diagnostics have significantly evolved with the use of positron emission tomography (PET) and advanced magnetic resonance imaging (MRI) techniques. In addition to anatomical MRI, these modalities may provide valuable information for several clinical applications such as differential diagnosis, delineation of tumor extent, prognostication, differentiation between tumor relapse and treatment-related changes, and the evaluation of response to anticancer therapy. In particular, joint recommendations of the Response Assessment in Neuro-Oncology (RANO) Group, the European Association of Neuro-oncology, and major European and American Nuclear Medicine societies highlighted that the additional clinical value of radiolabeled amino acids compared to anatomical MRI alone is outstanding and that its widespread clinical use should be supported. For advanced MRI and its steadily increasing use in clinical practice, the Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition provided more recently an updated acquisition protocol for the widely used dynamic susceptibility contrast perfusion MRI. Besides amino acid PET and perfusion MRI, other PET tracers and advanced MRI techniques (e.g. MR spectroscopy) are of considerable clinical interest and are increasingly integrated into everyday clinical practice. Nevertheless, these modalities have shortcomings which should be considered in clinical routine. This comprehensive review provides an overview of potential challenges, limitations, and pitfalls associated with PET imaging and advanced MRI techniques in patients with gliomas or brain metastases. Despite these issues, PET imaging and advanced MRI techniques continue to play an indispensable role in brain tumor management. Acknowledging and mitigating these challenges through interdisciplinary collaboration, standardized protocols, and continuous innovation will further enhance the utility of these modalities in guiding optimal patient care.
Ähnliche Arbeiten
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 · 28.927 Zit.
fastp: an ultra-fast all-in-one FASTQ preprocessor
2018 · 27.883 Zit.
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 · 21.269 Zit.
Robust uncertainty principles: exact signal reconstruction from highly incomplete frequency information
2006 · 15.628 Zit.
Image processing with ImageJ
2004 · 11.899 Zit.
Autoren
Institutionen
- University of Cologne(DE)
- University Hospital Cologne(DE)
- Forschungszentrum Jülich(DE)
- Mayo Clinic(US)
- RWTH Aachen University(DE)
- Heidelberg University(DE)
- University Hospital Heidelberg(DE)
- Erasmus MC Cancer Institute(NL)
- University of Wisconsin–Madison(US)
- University of Turin(IT)
- German Cancer Research Center(DE)
- Ludwig-Maximilians-Universität München(DE)
- Goethe University Frankfurt(DE)
- University Hospital Frankfurt(DE)
- Rigshospitalet(DK)
- Copenhagen University Hospital(DK)
- Moffitt Cancer Center(US)
- Center for Neuro-Oncology(US)
- Dana-Farber Cancer Institute(US)
- University of Zurich(CH)
- University Hospital of Zurich(CH)
- LMU Klinikum(DE)